Brukinsa (zanubrutinib) — CareFirst (Caremark)

Initial criteria

• Member had disease progression after receiving therapy for relapsed or refractory disease.
• Brukinsa will be used as a single agent.

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months